 Lantern Pharma LTRN, a clinical stage biotechnology company focused on leveraging artificial intelligence A.I., machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, announced today that it will make two presentations at the upcoming American Association for Cancer Research AACR 2020 Virtual Annual Meeting, a meeting of global leaders in cancer research taking place from June 22-24, 2020. Each presentation will examine Lantern Pharmas use of its A.I. platform, RADR Response Algorithm for Drug Positioning and Rescue, in the development of LP-184, one of three cancer drugs in Lantern Pharmas pipeline. 